Cargando…
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients...
Autores principales: | Iaffaioli, R. V., Tortoriello, A., Facchini, G., Santangelo, M., De Sena, G., Gesue, G., Bucci, L., Scaramellino, G., Anastasio, E., Finizio, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033957/ https://www.ncbi.nlm.nih.gov/pubmed/7577478 |
Ejemplares similares
-
Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007) -
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
por: Huebner, G, et al.
Publicado: (2009) -
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012) -
Carboplatin/vinorelbine: Worsening of lung adenocarcinoma: case report
Publicado: (2022) -
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)